CABA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cabaletta Bio Inc (CABA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak financial performance, no significant positive catalysts, and lacks strong trading signals. While the technical indicators are mixed, the lack of recent news, weak analyst sentiment, and poor options activity suggest a cautious approach.
The MACD is slightly positive (0.00806) but contracting, indicating limited momentum. RSI is neutral at 47.843, suggesting no clear overbought or oversold condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level (3.275) with support at 2.897 and resistance at 3.653. The stock's recent price action shows a -7.29% drop in the regular market, which is concerning.
The stock has a 4.59% chance of gaining in the next month based on similar candlestick patterns. Analysts maintain an Overweight rating, suggesting some long-term potential.
and net income (-$44.87M) despite some YoY improvement.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$44.87M (improved by 46.48% YoY), and a drop in EPS to -0.44 (-29.03% YoY). Gross margin remains at 0%, indicating no profitability.
Morgan Stanley recently lowered the price target from $22 to $14 but maintained an Overweight rating. The firm sees potential in small-to-mid cap biotech over the long term but acknowledges challenges in the near term.
